Aradigm CEO Will Shrank discusses the significant challenge payers face in predicting and managing the costs of cell and gene therapies due to their volatility and unpredictability.
Will Shrank
Advertisement
Will Shrank is CEO of Aradigm Health.
Articles by Will Shrank
Will Shrank, CEO of Aradigm Health, discusses the fragmented payment and delivery system and its impact on cell & gene therapies.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
2
Sanofi Officially Appoints Belén Garijo as Chief Executive Officer Following Shareholder Vote
3
Alternative Supply Chain Strategies Companies Should Prioritize
4
Using a Customer-Based Process to Synchronize Sales & Marketing Organizations in Pharma
5